BioMarin Pharmaceutical | BMRN - Ebit



金融业
股票价格
USD 55.95
资产
USD 11.72B
现金及等价物
USD 874.01M
销售成本
USD 276.29M
流动资产
USD 3.97B
流动负债
USD 1.66B
债务
USD 1.44B
EBIT
USD 105.61M
EBITDA
USD 146.05M
员工
3.04K
EPS每股收益
USD 1.2
股本和储备
USD 6.32B
销售毛利
USD 713.42M
债务利息支出
USD 63.3M
利息收入
USD 22.56M
贷款资金
USD 3.53B
市值
USD 10.66B
净收入
USD 44.76M
营业费用
USD 6.32B
营业利润
USD 105.61M
普通股股本
USD 193.54M
PE价格收益
21.07
税前利润
USD 141.2M
销售收入
USD 990M
销售和管理费用
USD 395.55M
股票
USD 1.78B
贸易债权人
USD 913.67M
应收帐款人
USD 1.06B


Ebit 更改 日
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Amgen USD 4.61B 777M 2026-06
Bayer EUR 755M 2.77B 2026-06
Biogen USD -243.8M 758.1M 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
Incyte USD 700.4M 356.23M 2026-06
Insmed USD -101.31M 98.97M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Moderna USD -815M 573M 2026-06
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
PTC Therapeutics USD 146.03M 100.14M 2026-06
Puma Biotechnology USD -2.2M 11.41M 2024-06
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sanofi EUR 2.18B 1.56B 2026-03
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
United Therapeutics USD 375.6M 49.8M 2026-06
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06